Increasing efficacy and reducing systemic absorption of brimonidine tartrate ophthalmic gels in rabbits

• Published in: Pharmaceutical development and technology Vol. 23; no. 3; p. 231
• Main Authors: Pang, Xiaochen, Li, Jiawei, Pi, Jiaxin, Qi, Dongli, Guo, Pan, Li, Nan, Wu, Yumei, Liu, Zhidong
• Format: Journal Article
• Language: English
• Published: England 16.03.2018
• Subjects: Brimonidine tartrate; systemic absorption; intraocular pressure; ophthalmic gels; UPLC–MS/MS
• ISSN: 1097-9867
• DOI: 10.1080/10837450.2017.1328693

Systemic absorption of ocularly administered Brimonidine Tartrate has been reported to give rise to several side-effects. Hence, it has become crucial to develop a delivery system that could increase efficacy and reduce systemic absorption. Therefore, the present work aims to develop Brimonidine Tartrate gels with different concentrations (0.05%, 0.1%, and 0.2% w/v, respectively) using Carbopol 974 P and HPMC E4M, and compare the therapeutic efficacy and systemic absorption with that of eye drop (0.2%, w/v) by UPLC-MS/MS. The result of histological analysis did not show any morphological or structural changes after the administration of formulations. In vitro residence time studies demonstrated that the gels exhibited a better precorneal residence time as compared with the eye drop. The gels with lower concentrations of the drug (0.05% and 0.1%, w/v) could significantly decrease intraocular pressure (IOP) in both normal and water-loaded rabbits as compared to the eye drop. Finally, the values of the ratio of AUC in comparison to eye drop showed the gels with lower concentrations of Brimonidine Tartrate could decrease the systemic absorption. From the result, it can be concluded the 0.1% ophthalmic gel has a potential to improve therapeutic efficacy and reduce the potential toxicity caused by systemic absorption.